Clinical Trial: NCT04001777
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Ascentage Pharma Group Inc. |
| Information Provided By: | Ascentage Pharma Group Inc. |
| Last Update Posted: | 2025-10-01 |
Study Overview
Brief Summary
There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naïve patients.
Official Title
Conditions
Intervention / Treatment
- Drug: APG-1252
- Drug: Osimertinib Mesylate Tablets
Other Study ID Numbers
- APG1252NC101
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Ascentage Pharma Group Inc. |
| Information Provided By: | Ascentage Pharma Group Inc. |
| Last Update Posted: | 2025-10-01 |
Study Overview
Brief Summary
There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naïve patients.
Official Title
Conditions
Intervention / Treatment
- Drug: APG-1252
- Drug: Osimertinib Mesylate Tablets
Other Study ID Numbers
- APG1252NC101